{"id":"scopolamine-transdermal","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Dry mouth"},{"rate":"10-20","effect":"Drowsiness"},{"rate":"5-15","effect":"Blurred vision"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Mydriasis (dilated pupils)"}]},"_chembl":{"chemblId":"CHEMBL2251240","moleculeType":"Small molecule","molecularWeight":"438.32"},"_dailymed":{"setId":"cb93bfad-3e37-4a27-92f6-f21703ae7bdf","title":"SCOPOLAMINE TRANSDERMAL SYSTEM PATCH, EXTENDED RELEASE [PADAGIS ISRAEL PHARMACEUTICALS LTD]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Scopolamine is an anticholinergic agent that antagonizes muscarinic acetylcholine receptors, particularly in the chemoreceptor trigger zone and vestibular nuclei of the brain. By blocking these receptors, it suppresses signals that trigger nausea and vomiting. The transdermal formulation provides sustained drug delivery over several days, making it effective for motion sickness and postoperative nausea prevention.","oneSentence":"Scopolamine blocks muscarinic acetylcholine receptors in the central nervous system to prevent nausea and vomiting.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:28.495Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of motion sickness"},{"name":"Prevention of postoperative nausea and vomiting"}]},"trialDetails":[{"nctId":"NCT04366518","phase":"EARLY_PHASE1","title":"Toward a Computationally-Informed, Personalized Treatment for Hallucinations","status":"RECRUITING","sponsor":"Yale University","startDate":"2021-07-15","conditions":"Hallucinations, Auditory, Psychosis","enrollment":35},{"nctId":"NCT02202369","phase":"PHASE4","title":"Multimodal Analgesia vs. Routine Care Pain Management for Lumbar Spine Fusion Surgery: A Prospective Randomized Study","status":"SUSPENDED","sponsor":"OrthoCarolina Research Institute, Inc.","startDate":"2015-06-25","conditions":"Single Level Lumbar Decompression and Fusion Spine Surgery","enrollment":50},{"nctId":"NCT05021263","phase":"PHASE3","title":"Does IV Magnesium Improve Quality of Recovery With ERAS Protocols in Laparoscopic Colorectal Surgery?","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2022-05-27","conditions":"Colo-rectal Cancer, Anesthesia","enrollment":90},{"nctId":"NCT03435003","phase":"PHASE4","title":"Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy","status":"COMPLETED","sponsor":"Stony Brook University","startDate":"2017-08-28","conditions":"Post-operative Nausea and Vomiting, Laparoscopic Sleeve Gastrectomy","enrollment":83},{"nctId":"NCT04008264","phase":"","title":"A Novel Usage of Transdermal Scopolamine in Reducing Narcotic Usage in Outpatient Hand Surgery","status":"COMPLETED","sponsor":"Alexander M Spiess, MD","startDate":"2019-06-25","conditions":"Post Operative Pain Management","enrollment":74},{"nctId":"NCT04272255","phase":"PHASE3","title":"Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness","status":"UNKNOWN","sponsor":"Repurposed Therapeutics, Inc.","startDate":"2019-04-22","conditions":"Motion Sickness","enrollment":300},{"nctId":"NCT04184115","phase":"PHASE3","title":"Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness","status":"COMPLETED","sponsor":"Repurposed Therapeutics, Inc.","startDate":"2019-06-09","conditions":"Motion Sickness","enrollment":102},{"nctId":"NCT03920644","phase":"PHASE3","title":"Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels","status":"UNKNOWN","sponsor":"Naval Aeromedical Research Unit, Dayton","startDate":"2019-04","conditions":"Prevention of Nausea Associated With Motion Sickness, Treatment of Nausea Associated With Motion Sickness","enrollment":320},{"nctId":"NCT02839135","phase":"PHASE1","title":"A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-05-13","conditions":"Motion Sickness","enrollment":128},{"nctId":"NCT02410460","phase":"NA","title":"Anesthetics in Rhytidoplasty - A Comparison Study","status":"COMPLETED","sponsor":"Mercy Facial Plastic Surgery Center","startDate":"2013-09","conditions":"Rhytidoplasty","enrollment":30},{"nctId":"NCT01592708","phase":"NA","title":"Study of Anesthesia Techniques to Reduce Nausea and Vomiting After Jaw Corrective Surgery","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2012-06","conditions":"Post-operative Nausea, Post-operative Vomiting, Nausea Persistent","enrollment":233},{"nctId":"NCT00717054","phase":"NA","title":"Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting","status":"COMPLETED","sponsor":"Drexel University","startDate":"2008-02","conditions":"Nausea, Vomiting","enrollment":115},{"nctId":"NCT00659737","phase":"NA","title":"Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting","status":"COMPLETED","sponsor":"Drexel University College of Medicine","startDate":"2008-04","conditions":"Nausea, Vomiting","enrollment":115},{"nctId":"NCT00374478","phase":"PHASE2","title":"Effects of Transdermal Scopolamine on Occupational Performance","status":"COMPLETED","sponsor":"Boston University","startDate":"2005-04","conditions":"Motion Sickness","enrollment":33}],"_emaApprovals":[],"_faersSignals":[{"count":153,"reaction":"PRODUCT ADHESION ISSUE"},{"count":81,"reaction":"OFF LABEL USE"},{"count":51,"reaction":"WRONG TECHNIQUE IN PRODUCT USAGE PROCESS"},{"count":41,"reaction":"DIZZINESS"},{"count":32,"reaction":"NAUSEA"},{"count":27,"reaction":"DRUG INEFFECTIVE"},{"count":22,"reaction":"VISION BLURRED"},{"count":20,"reaction":"PRODUCT QUALITY ISSUE"},{"count":15,"reaction":"DRY MOUTH"},{"count":15,"reaction":"VOMITING"}],"_approvalHistory":[{"date":"20260209","type":"SUPPL","sponsor":"PADAGIS US","applicationNumber":"ANDA078830"},{"date":"20231027","type":"SUPPL","sponsor":"PADAGIS US","applicationNumber":"ANDA078830"},{"date":"20260209","type":"SUPPL","sponsor":"PADAGIS US","applicationNumber":"ANDA078830"},{"date":"20150130","type":"ORIG","sponsor":"PADAGIS US","applicationNumber":"ANDA078830"}],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Transderm Scop"],"phase":"marketed","status":"active","brandName":"scopolamine transdermal","genericName":"scopolamine transdermal","companyName":"Stony Brook University","companyId":"stony-brook-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Scopolamine is a small molecule used in transdermal form to prevent nausea, vomiting, motion sickness, and postoperative nausea and vomiting. It has been studied in clinical trials for its effectiveness in these conditions, including a randomized, double-blind comparison with aprepitant for preventing postoperative nausea and vomiting.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"supplemented","approval_date":"2015-01-30T00:00:00.000Z","mah":"PADAGIS US","brand_name_local":null,"application_number":"ANDA078830"}],"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}